This cell-type specificity may explain why CD27-targeted therapeutic strategies are associated with lower risks of systemic adverse reactions, echoing recent experiences in cancer immunotherapy, where targeting costimulatory/coinhibitory molecules typically results in manageable safety profiles. The gene discussed is CD27; the disease is cancer.